Skip to content Skip to sidebar Skip to footer
Immutep
Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?
Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company's clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy's Laboratories. What…
SKS Technologies
SKS Technologies (ASX:SKS) Surges 8% on A$60M Contract Wins and FY26 Guidance Upgrade- Buy or Take Profits?
SKS Technologies jumps on new contracts and stronger margins SKS Technologies (ASX: SKS) jumped 8.5 per cent to A$3.83 on Thursday after landing A$60 million in new contracts and raising its profit outlook. The company now expects to bring in A$340 million in revenue this financial year, up from its earlier forecast of A$320 million.…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here